Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study

Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there was a clinical impact of this statement in the anemia management of chronic kidney disease (CKD) patients treated with ESAs not on dialysis in routine clinical practice in Spain. Methods: This was an observational and cross-sectional study carried out in CKD patients not on dialysis in Spain who initiated ESA treatment (naïve), or were shifted from a previous ESA to another ESAs (converted) since January 2011. Results: Of 441 patients evaluated, 67.6% were naïve and 32.4% were converted. At the study visit, 42.5% of naïve patients achieved the Hb target of 11-12 g/dL, with a mean Hb of 11.3±1.3 g/dL (vs 10.1±0.9 g/dL at the start of ESA therapy). Only 35.3% of converted patients maintained Hb levels within the recommended target at the study visit. Yet, 8.2% of naïve patients and 7.9% of those converted had Hb levels &gt;13 g/dL. Hb levels were similar across subgroups of patients, regardless of the presence of significant comorbidities. Conclusions: Anemia management in CKD patients treated with ESAs by Spanish nephrologists seems to be aimed at preventing Hb levels <11 g/dL, while <50% of patients were within the narrow recommended Hb target range. This, together with the lack of individualization in Hb targets according to patients' comorbidities show that there is still room for improvement in renal anemia management in the clinical setting.

Saved in:
Bibliographic Details
Main Authors: Martínez-Castelao,Alberto, Cases,Aleix, Torre Carballada,Alberto, Torralba Iranzo,Javier, Bronsoms,Josep, Vallès-Prats,Martí, Torán Monserrat,Daniel, Masso Jimenez,Elisabet
Format: Digital revista
Language:English
Published: Sociedad Española de Nefrología 2015
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952015000200010
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0211-69952015000200010
record_format ojs
spelling oai:scielo:S0211-699520150002000102015-07-15Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA studyMartínez-Castelao,AlbertoCases,AleixTorre Carballada,AlbertoTorralba Iranzo,JavierBronsoms,JosepVallès-Prats,MartíTorán Monserrat,DanielMasso Jimenez,Elisabet Anemia Chronic kidney disease Hemoglobin Erythropoiesis-stimulating agents Observational Study Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there was a clinical impact of this statement in the anemia management of chronic kidney disease (CKD) patients treated with ESAs not on dialysis in routine clinical practice in Spain. Methods: This was an observational and cross-sectional study carried out in CKD patients not on dialysis in Spain who initiated ESA treatment (naïve), or were shifted from a previous ESA to another ESAs (converted) since January 2011. Results: Of 441 patients evaluated, 67.6% were naïve and 32.4% were converted. At the study visit, 42.5% of naïve patients achieved the Hb target of 11-12 g/dL, with a mean Hb of 11.3±1.3 g/dL (vs 10.1±0.9 g/dL at the start of ESA therapy). Only 35.3% of converted patients maintained Hb levels within the recommended target at the study visit. Yet, 8.2% of naïve patients and 7.9% of those converted had Hb levels &gt;13 g/dL. Hb levels were similar across subgroups of patients, regardless of the presence of significant comorbidities. Conclusions: Anemia management in CKD patients treated with ESAs by Spanish nephrologists seems to be aimed at preventing Hb levels <11 g/dL, while <50% of patients were within the narrow recommended Hb target range. This, together with the lack of individualization in Hb targets according to patients' comorbidities show that there is still room for improvement in renal anemia management in the clinical setting.Sociedad Española de NefrologíaNefrología (Madrid) v.35 n.2 20152015-01-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952015000200010en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Martínez-Castelao,Alberto
Cases,Aleix
Torre Carballada,Alberto
Torralba Iranzo,Javier
Bronsoms,Josep
Vallès-Prats,Martí
Torán Monserrat,Daniel
Masso Jimenez,Elisabet
spellingShingle Martínez-Castelao,Alberto
Cases,Aleix
Torre Carballada,Alberto
Torralba Iranzo,Javier
Bronsoms,Josep
Vallès-Prats,Martí
Torán Monserrat,Daniel
Masso Jimenez,Elisabet
Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
author_facet Martínez-Castelao,Alberto
Cases,Aleix
Torre Carballada,Alberto
Torralba Iranzo,Javier
Bronsoms,Josep
Vallès-Prats,Martí
Torán Monserrat,Daniel
Masso Jimenez,Elisabet
author_sort Martínez-Castelao,Alberto
title Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
title_short Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
title_full Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
title_fullStr Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
title_full_unstemmed Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study
title_sort clinical impact of the erbp working group 2010 recommendations for the anemia management in chronic kidney disease not on dialysis: acerca study
description Background and objective: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there was a clinical impact of this statement in the anemia management of chronic kidney disease (CKD) patients treated with ESAs not on dialysis in routine clinical practice in Spain. Methods: This was an observational and cross-sectional study carried out in CKD patients not on dialysis in Spain who initiated ESA treatment (naïve), or were shifted from a previous ESA to another ESAs (converted) since January 2011. Results: Of 441 patients evaluated, 67.6% were naïve and 32.4% were converted. At the study visit, 42.5% of naïve patients achieved the Hb target of 11-12 g/dL, with a mean Hb of 11.3±1.3 g/dL (vs 10.1±0.9 g/dL at the start of ESA therapy). Only 35.3% of converted patients maintained Hb levels within the recommended target at the study visit. Yet, 8.2% of naïve patients and 7.9% of those converted had Hb levels &gt;13 g/dL. Hb levels were similar across subgroups of patients, regardless of the presence of significant comorbidities. Conclusions: Anemia management in CKD patients treated with ESAs by Spanish nephrologists seems to be aimed at preventing Hb levels <11 g/dL, while <50% of patients were within the narrow recommended Hb target range. This, together with the lack of individualization in Hb targets according to patients' comorbidities show that there is still room for improvement in renal anemia management in the clinical setting.
publisher Sociedad Española de Nefrología
publishDate 2015
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0211-69952015000200010
work_keys_str_mv AT martinezcastelaoalberto clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT casesaleix clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT torrecarballadaalberto clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT torralbairanzojavier clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT bronsomsjosep clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT vallespratsmarti clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT toranmonserratdaniel clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
AT massojimenezelisabet clinicalimpactoftheerbpworkinggroup2010recommendationsfortheanemiamanagementinchronickidneydiseasenotondialysisacercastudy
_version_ 1755936404193411072